Application Data
(Figure 6 ACE2-RBD binding inhibitory ELISAAntibodies: SARS-CoV-2 (COVID-19) Spike RBD Antibodies, SD9853 (A10) and AAA11055 (E10). ACE2-RBD binding inhibitory ELISA was performed using RBD protein of SARS-CoV-2 variants (wild-type and alpha) as coating antigens at 1ug/mL and the anti-SARS-CoV-2 (COVID-19) RBD antibody (SD9853 and AAA11055) as the capture antibody, followed by incubation with 20 ng/mL human ACE2-Fc. Bound h-ACE2-Fc was detected with a goat anti-human IgG-HRP conjugate (1:20,000 dilution) using the TMB chromogenic substrate system. Both SD9853 (A10) and AAA11055 (E10) exhibited a dose dependent inhibitory effect on ACE2 binding to RBDs of wild-type and alpha strains, and the combination of the two (A10+E10) showed a significantly synergistic effect.)
SARS-CoV-2 (COVID-19) Spike Neutralization Recombinant Antibody | SARS-CoV-2 recombinant antibody
SARS-CoV-2 (COVID-19) Spike Neutralization Single Domain Antibody [E10]
Application Data
(Figure 6 ACE2-RBD binding inhibitory ELISAAntibodies: SARS-CoV-2 (COVID-19) Spike RBD Antibodies, SD9853 (A10) and AAA11055 (E10). ACE2-RBD binding inhibitory ELISA was performed using RBD protein of SARS-CoV-2 variants (wild-type and alpha) as coating antigens at 1ug/mL and the anti-SARS-CoV-2 (COVID-19) RBD antibody (SD9853 and AAA11055) as the capture antibody, followed by incubation with 20 ng/mL human ACE2-Fc. Bound h-ACE2-Fc was detected with a goat anti-human IgG-HRP conjugate (1:20,000 dilution) using the TMB chromogenic substrate system. Both SD9853 (A10) and AAA11055 (E10) exhibited a dose dependent inhibitory effect on ACE2 binding to RBDs of wild-type and alpha strains, and the combination of the two (A10+E10) showed a significantly synergistic effect.)
Application Data
(Figure 6 ACE2-RBD binding inhibitory ELISAAntibodies: SARS-CoV-2 (COVID-19) Spike RBD Antibodies, SD9853 (A10) and AAA11055 (E10). ACE2-RBD binding inhibitory ELISA was performed using RBD protein of SARS-CoV-2 variants (wild-type and alpha) as coating antigens at 1ug/mL and the anti-SARS-CoV-2 (COVID-19) RBD antibody (SD9853 and AAA11055) as the capture antibody, followed by incubation with 20 ng/mL human ACE2-Fc. Bound h-ACE2-Fc was detected with a goat anti-human IgG-HRP conjugate (1:20,000 dilution) using the TMB chromogenic substrate system. Both SD9853 (A10) and AAA11055 (E10) exhibited a dose dependent inhibitory effect on ACE2 binding to RBDs of wild-type and alpha strains, and the combination of the two (A10+E10) showed a significantly synergistic effect.)
Application Data
(Figure 5 Pseudovirus neutralization assayAntibodies: SARS-CoV-2 (COVID-19) Spike RBD Antibodies, SD9853 (A10) and AAA11055 (E10). Luciferase reporter virus-like particles and 293T-hsACE2 cells were used for the assay. After 72 hrs incubation infectivity was measured by luciferase expression using Promega Renilla-Glo Luciferase Assay System. Infectivity was measured as RLUs and no sdAb control was set to 100% infectivity. Neutralization activity of SD9853 (A10) and AAA11055 (E10) was measured over a serial dilution series to determine the half-maximal inhibitory concentration (IC50). Both SD9853 (A10) and AAA11055 (E10) exhibited a dose dependent neutralizing effect on alpha pseudoviruses, and the combination of the two showed a significantly synergistic effect.)
Application Data
(Figure 5 Pseudovirus neutralization assayAntibodies: SARS-CoV-2 (COVID-19) Spike RBD Antibodies, SD9853 (A10) and AAA11055 (E10). Luciferase reporter virus-like particles and 293T-hsACE2 cells were used for the assay. After 72 hrs incubation infectivity was measured by luciferase expression using Promega Renilla-Glo Luciferase Assay System. Infectivity was measured as RLUs and no sdAb control was set to 100% infectivity. Neutralization activity of SD9853 (A10) and AAA11055 (E10) was measured over a serial dilution series to determine the half-maximal inhibitory concentration (IC50). Both SD9853 (A10) and AAA11055 (E10) exhibited a dose dependent neutralizing effect on alpha pseudoviruses, and the combination of the two showed a significantly synergistic effect.)
Application Data
(Figure 4 Pseudovirus neutralization assayAntibodies: SARS-CoV-2 (COVID-19) Spike RBD Antibodies, SD9853 (A10) and AAA11055 (E10). Luciferase reporter virus-like particles and 293T-hsACE2 cells were used for the assay. After 72 hrs incubation infectivity was measured by luciferase expression using Promega Renilla-Glo Luciferase Assay System. Infectivity was measured as RLUs and no sdAb control was set to 100% infectivity. Neutralization activity of SD9853 (A10) and AAA11055 (E10) was measured over a serial dilution series to determine the half-maximal inhibitory concentration (IC50). Both SD9853 (A10) and AAA11055 (E10) exhibited a dose dependent neutralizing effect on wild-type pseudoviruses, and the combination of the two showed a significantly synergistic effect.)
Application Data
(Figure 4 Pseudovirus neutralization assayAntibodies: SARS-CoV-2 (COVID-19) Spike RBD Antibodies, SD9853 (A10) and AAA11055 (E10). Luciferase reporter virus-like particles and 293T-hsACE2 cells were used for the assay. After 72 hrs incubation infectivity was measured by luciferase expression using Promega Renilla-Glo Luciferase Assay System. Infectivity was measured as RLUs and no sdAb control was set to 100% infectivity. Neutralization activity of SD9853 (A10) and AAA11055 (E10) was measured over a serial dilution series to determine the half-maximal inhibitory concentration (IC50). Both SD9853 (A10) and AAA11055 (E10) exhibited a dose dependent neutralizing effect on wild-type pseudoviruses, and the combination of the two showed a significantly synergistic effect.)
ELISA
(Figure 3 ELISA Validation with RBDs of SARS-CoV-2 Variants Antibodies: SARS-CoV-2 (COVID-19) Spike RBD Antibody, AAA11055. A direct ELISA was performed using RBD protein of SARS-CoV-2 variants (wild-type, alpha, beta, gamma and Delta) as coating antigens at 1ug/mL and the anti-SARS-CoV-2 (COVID-19) RBD antibody (SD9853) as the capture antibody, followed by anti-cMyc-tag antibody (PM-7669) at 1ug/mL. Secondary: Goat anti-mouse IgG HRP conjugate at 1:5000 dilution. SD9853 binds to RBDs of all the variants tested.)
ELISA
(Figure 3 ELISA Validation with RBDs of SARS-CoV-2 Variants Antibodies: SARS-CoV-2 (COVID-19) Spike RBD Antibody, AAA11055. A direct ELISA was performed using RBD protein of SARS-CoV-2 variants (wild-type, alpha, beta, gamma and Delta) as coating antigens at 1ug/mL and the anti-SARS-CoV-2 (COVID-19) RBD antibody (SD9853) as the capture antibody, followed by anti-cMyc-tag antibody (PM-7669) at 1ug/mL. Secondary: Goat anti-mouse IgG HRP conjugate at 1:5000 dilution. SD9853 binds to RBDs of all the variants tested.)
ELISA
(Figure 2 ACE2-RBD binding inhibitory ELISAAntibodies: SARS-CoV-2 (COVID-19) Spike RBD Antibodies, AAA11055. ACE2-RBD binding inhibitory ELISA was performed using RBD protein of SARS-CoV-2 variants (wild-type, alpha, beta, epsilon, gamma and kappa) as coating antigens at 1ug/mL and the anti-SARS-CoV-2 (COVID-19) RBD antibody AAA11055 as the capture antibody, followed by incubation with 20 ng/mL human ACE2-Fc. Bound h-ACE2-Fc was detected with a goat anti-human IgG-HRP conjugate (1:20,000 dilution) using the TMB chromogenic substrate system. AAA11055 exhibited a dose dependent inhibitory effect on ACE2 binding to RBDs of all the variants tested.)
ELISA
(Figure 2 ACE2-RBD binding inhibitory ELISAAntibodies: SARS-CoV-2 (COVID-19) Spike RBD Antibodies, AAA11055. ACE2-RBD binding inhibitory ELISA was performed using RBD protein of SARS-CoV-2 variants (wild-type, alpha, beta, epsilon, gamma and kappa) as coating antigens at 1ug/mL and the anti-SARS-CoV-2 (COVID-19) RBD antibody AAA11055 as the capture antibody, followed by incubation with 20 ng/mL human ACE2-Fc. Bound h-ACE2-Fc was detected with a goat anti-human IgG-HRP conjugate (1:20,000 dilution) using the TMB chromogenic substrate system. AAA11055 exhibited a dose dependent inhibitory effect on ACE2 binding to RBDs of all the variants tested.)
Application Data
(Figure 1 Pseudovirus neutralization assayAntibodies: SARS-CoV-2 (COVID-19) Spike RBD Antibodies, AAA11055 (E10). Luciferase reporter virus-like particles and 293T-hsACE2 cells were used for the assay. After 72 hrs incubation infectivity was measured by luciferase expression using Promega Renilla-Glo Luciferase Assay System. Infectivity was measured as RLUs and no sdAb control was set to 100% infectivity. Neutralization activity of AAA11055 (E10) was measured over a serial dilution to determine the half-maximal inhibitory concentration (IC50). AAA11055 (E10) exhibited a dose dependent neutralizing effect on all the variant pseudoviruses tested.)
Application Data
(Figure 1 Pseudovirus neutralization assayAntibodies: SARS-CoV-2 (COVID-19) Spike RBD Antibodies, AAA11055 (E10). Luciferase reporter virus-like particles and 293T-hsACE2 cells were used for the assay. After 72 hrs incubation infectivity was measured by luciferase expression using Promega Renilla-Glo Luciferase Assay System. Infectivity was measured as RLUs and no sdAb control was set to 100% infectivity. Neutralization activity of AAA11055 (E10) was measured over a serial dilution to determine the half-maximal inhibitory concentration (IC50). AAA11055 (E10) exhibited a dose dependent neutralizing effect on all the variant pseudoviruses tested.)
Hui et al. Int J Infect Dis. 2020;91:264-266.
Belouzard et al. Viruses. 2012;4(6):1011-33.
Lee et al. J Virol. 2006;80(8):4079-87.
Wan et al. J Virol. 2020.
Wrapp et al. Science. 2020.
NCBI and Uniprot Product Information
Similar Products
Product Notes
The SARS-CoV-2 (Catalog #AAA11055) is a Recombinant Antibody produced from Llama and is intended for research purposes only. The product is available for immediate purchase. The SARS-CoV-2 (COVID-19) Spike Neutralization Single Domain Antibody [E10] reacts with Virus and may cross-react with other species as described in the data sheet. AAA Biotech's SARS-CoV-2 (COVID-19) Spike Neutralization can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA), Neutralization (NEUT). Researchers should empirically determine the suitability of the SARS-CoV-2 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "SARS-CoV-2 (COVID-19) Spike Neutralization, Monoclonal Recombinant Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.